Identifying DASH Adherence Patterns and Their Association With Dietary Behaviors Among Adults With Hypertension.

Res Nurs HealthMay 4, 2026 (epub)
Clinical ResearchCardiologyInternal Medicine (General)Preventive Medicine / Public HealthOpen access

Youran Lee, Melissa C Kay, Anushka Palipana et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial analyzed DASH diet adherence patterns among 301 adults with hypertension. The study identified three adherence subgroups: low (44.2%), high (41.2%), and mixed-pattern (14.6%). The mean DASH adherence score was low at 3.13 ± 1.35, with significant differences in intuitive eating behaviors across subgroups.

Key findings

  • DASH adherence was low with a mean score of 3.13 ± 1.35.
  • Three adherence subgroups were identified: low (44.2%), high (41.2%), and mixed-pattern (14.6%).
  • Significant differences in intuitive eating behaviors were observed, particularly in unconditional permission to eat (p < 0.0001).
  • The low-adherence group scored higher on hunger cues compared to the high-adherence group.

Why it matters

Understanding DASH adherence patterns and their association with dietary behaviors can help clinicians tailor dietary guidance for patients with hypertension, potentially improving adherence and cardiovascular health outcomes.

Source

PubMed · PMID 42080799Free full text on PubMed Central

Published in Res Nurs Health. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.